论文部分内容阅读
目的分析降压调脂在社区治疗老年人高血压合并高脂血症的临床疗效。方法 70例社区卫生服务站老年高血压合并高脂血症患者,随机分为观察组与对照组,每组35例。观察组给予氨氯地平阿托伐他汀钙联合辛伐他汀治疗,对照组给予氨氯地平或卡托普利治疗。对比两组治疗前后收缩压、舒张压、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平及心脑血管事件发生情况。结果治疗前两组血压及血脂水平比较差异均无统计学意义(P>0.05);治疗后两组收缩压及舒张压均较治疗前明显降低,且观察组降低幅度大于对照组,差异均具有统计学意义(P<0.05);治疗后观察组TG、TC、LDL-C较治疗前明显降低,HDL-C较治疗前明显升高,且观察组TG、TC、LDL-C明显低于对照组,HDL-C明显高于对照组,差异均具有统计学意义(P<0.05)。观察组心脑血管事件发生率为2.86%,低于对照组的17.14%,差异具有统计学意义(P<0.05)。结论降压调脂用于社区老年人高血压合并高脂血症中能改善患者血压和血脂水平,降低心脑血管事件发生率,值得推广。
Objective To analyze the clinical efficacy of antihypertensive lipid lowering in the treatment of hypertension in elderly patients with hyperlipidemia. Methods 70 cases of community health service station elderly hypertensive patients with hyperlipidemia were randomly divided into observation group and control group, 35 cases in each group. The observation group was given amlodipine atorvastatin calcium combined with simvastatin, while the control group was treated with amlodipine or captopril. Before and after treatment, systolic blood pressure, diastolic blood pressure, triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) The incident occurred. Results There was no significant difference in blood pressure and blood lipid level between the two groups before treatment (P> 0.05). After treatment, the systolic and diastolic blood pressures of the two groups were significantly lower than those before treatment, and the reduction rate in the observation group was greater than that in the control group TG, TC, LDL-C in the observation group were significantly lower than those before treatment, HDL-C was significantly higher than before treatment, and TG, TC, LDL-C in the observation group was significantly lower than the control group Group, HDL-C was significantly higher than the control group, the difference was statistically significant (P <0.05). The incidence of cardiovascular events in observation group was 2.86%, which was lower than that in control group (17.14%), the difference was statistically significant (P <0.05). Conclusion The hypotensive lipid-lowering lipid used in community elderly with hypertension and hyperlipidemia can improve blood pressure and blood lipid levels and reduce the incidence of cardiovascular events, which is worth promoting.